# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-25-070119
**Filing Date:** 2025-7
**Character Count:** 2988
**Document Hash:** f8b02067d31dad09ed36c2c815d0eb70
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-070119.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001213900-25-070119

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250731

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

**INMED PHARMACEUTICALS INC.**<br> Suite 1445 – 885 West Georgia St.

Vancouver, British Columbia, Canada

V6C 3E8

**<u>VIA EDGAR</u>**

July 31, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

---

| | |
|:---|:---|
| **Re:** | **InMed Pharmaceuticals Inc. – Withdrawal of Acceleration<br> Request for Registration Statement on Form S-1 <br> Originally Filed on July 9, 2025** |

---

**and**

**Acceleration Request for Pre-Effective Amendment No. 1 to<br> Registration Statement on Form S-1**

**Filed July 31, 2025** 

**File No. 333-288594**

Ladies and Gentlemen:

InMed Pharmaceuticals Inc. (the "**<u>Company</u>**") hereby respectfully withdraws its request, previously submitted to the Securities and Exchange Commission (the "**<u>Commission</u>**") on July 14, 2025 (the "**<u>Prior Acceleration Request</u>**"), for the effectiveness of the Company's Registration Statement on Form S-1 (File No. 333-288594) originally filed with the Commission on July 9, 2025 (the "**<u>Registration Statement</u>**") be accelerated to occur at 5:00 p.m. (Eastern Time) on July 16, 2025 at 5:00 p.m., or as soon thereafter as practicable.

The Company has filed a Pre-Effective Amendment No. 1 to the Registration Statement via EDGAR on the date hereof and, pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby now requests that the effective date and time of the Registration Statement be accelerated to 5:00 p.m. (Eastern Time) on August 1, 2025, or as soon thereafter as practicable. This letter supercedes and replaces the Prior Acceleration Request in its entirety.

If you have any questions regarding this request, please contact Scott R. Saks of Norton Rose Fulbright US LLP at (212) 318-3151.

---

| |
|:---|
| Sincerely, |
| **INMED PHARMACEUTICALS INC.** |
| /s/ Eric A. Adams |
| Eric A. Adams |
| President and Chief Executive Officer |

---

cc: Netta Jagpal, *InMed Pharmaceuticals Inc.* <br> Scott R. Saks, *Norton Rose Fulbright US LLP* <br> Trevor Zeyl, *Norton Rose Fulbright Canada LLP*